Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. (2015)
Attributed to:
Rare disease use of clinical trial simulation for the chioce and optimization of study designs/Priomedchild Call/ER
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ejps.2014.10.018
PubMed Identifier: 25444842
Publication URI: http://europepmc.org/abstract/MED/25444842
Type: Journal Article/Review
Volume: 67
Parent Publication: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 0928-0987